Clinical and pathological features by CD1d immunoreactivity score
| Feature | Immunoreactivity score, n (%) | p Value | |
|---|---|---|---|
| Low (<50), n=126 | High (≥50), n=145 | ||
| Age at surgery (years) | |||
| <65 | 90 (71.4) | 98 (67.6) | 0.512 |
| ≥65 | 36 (28.6) | 47 (32.4) | |
| Sex | |||
| Female | 47 (37.3) | 49 (33.8) | 0.611 |
| Male | 79 (62.7) | 96 (66.2) | |
| Symptoms at presentation | |||
| Yes | 66 (52.4) | 63 (43.4) | 0.146 |
| No | 60 (47.6) | 82 (56.6) | |
| 2002 primary tumour classification | |||
| pT1a | 50 (39.7) | 40 (27.6) | 0.011 |
| pT1b | 34 (27.0) | 27 (18.6) | |
| pT2 | 10 (7.9) | 23 (15.9) | |
| pT3a | 18 (14.3) | 37 (25.5) | |
| pT3b | 13 (10.3) | 15 (10.3) | |
| pT3c | 0 (0.0) | 3 (2.1) | |
| pT4 | 1 (0.8) | 0 (0.0) | |
| Regional lymph node involvement | |||
| pNX/pN0 | 124 (98.4) | 141 (97.2) | 0.689 |
| pN1/pN2 | 2 (1.6) | 4 (2.8) | |
| 2002 TNM stage groupings | |||
| I | 83 (65.9) | 67 (46.2) | 0.011 |
| II | 10 (7.9) | 23 (15.9) | |
| III | 31 (24.6) | 52 (35.9) | |
| IV | 2 (1.6) | 3 (2.1) | |
| Nuclear grade | |||
| 1 | 28 (22.2) | 11 (7.6) | 0.000 |
| 2 | 83 (65.9) | 75 (51.7) | |
| 3 | 11 (8.7) | 42 (29.0) | |
| 4 | 4 (3.2) | 17 (11.7) | |
| Coagulative tumour necrosis | |||
| Yes | 24 (19.0) | 41 (28.3) | 0.880 |
| No | 102 (81.0) | 104 (71.7) | |
| Sarcomatoid differentiation | |||
| Yes | 1 (0.8) | 8 (5.5) | 0.040 |
| No | 125 (99.2) | 137 (94.5) | |
| Lymphovascular invasion | |||
| Yes | 8 (6.3) | 20 (13.8) | 0.048 |
| No | 118 (93.7) | 125 (86.2) | |
The staining intensity and percentage of positive tumour cells were recorded. The immunoreactive score was calculated as described in the Materials and methods section.
TNM, tumour, node and metastases.